1. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. Issue 8 (August 2021) Authors: Li, Edward; Mezzio, Dylan J.; Campbell, David; Campbell, Kim; Lyman, Gary H. Journal: JCO oncology practice Issue: Volume 17:Issue 8(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗